Why is fair value unavailable for IR MED Inc (OTC-IRME) stock?

A reliable fair value estimate is not currently available for IR MED Inc (OTC-IRME). This generally means the latest dataset does not contain enough valid inputs for the valuation models supported by PriceToWorth. The site does not substitute zero or publish an unsupported estimate; availability may change when updated financial data or applicable model inputs become available.

How is the financial health of IR MED Inc?

The current financial health read for IR MED Inc (OTC-IRME) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

When is IR MED Inc's next earnings date?

The next earnings date currently listed for IR MED Inc (OTC-IRME) is December 2, 2026.

Does IR MED Inc (OTC-IRME) pay dividends?

The latest available data indicates no current dividend yield for IR MED Inc (OTC-IRME).

What is the market capitalization of IR MED Inc?

The current market capitalization listed for IR MED Inc is 234.041 K.

What is the enterprise value of IR MED Inc?

The current enterprise value listed for IR MED Inc is 409.896 K. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

What is the ticker symbol for IR MED Inc?

The ticker symbol for IR MED Inc is OTC-IRME, and the stock is listed on OTC Markets.

Where is IR MED Inc (OTC-IRME) listed?

IR MED Inc (OTC-IRME) is listed on OTC Markets.

What is the debt-to-total-capital ratio for IR MED Inc?

The current debt-to-total-capital ratio listed for IR MED Inc is 52.9%, which helps investors evaluate the company’s financing structure and leverage profile.

IR MED Inc (IRME) Fair Value & Stock Analysis

IR MED Inc (IRME)

IR-Med Inc. is a healthcare company focused on developing non-invasive medical devices for a range of clinical uses. Its development pipeline includes PressureSafe, a handheld optical monitoring device intended to support early identification of pressure injuries to the skin and underlying tissue associated with prolonged pressure during bed confinement. The company is also developing DiaSafe, a handheld optical monitoring device designed to help detect diabetic foot ulcers in the lower limb, and Nobiotics, an otoscope intended to provide physicians with an immediate indication of middle-ear conditions in children. IR-Med is headquartered in Rosh Pinna, Israel, and its common stock trades on OTC Markets under the symbol IRME.

Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.

Ticker	Fair Value	Analyst Price Target	Analyst Target Upside/Downside	Overall Financial Health	Dividend Yield	Next Earnings Date	Market Cap	Enterprise Value	Total Debt / Total Capital	Altman Z-Score	Free Cash Flow / Net Income
OTC-IRME	Not available	Not available	Not available	Weak	0.0%	December 2, 2026	234.041 K	409.896 K	52.9%	-418.7	35.6%